Core Viewpoint - Insulet Corporation is under investigation for potential securities fraud and unlawful business practices following a recent product issue that led to a significant drop in its stock price [1][3]. Group 1: Company Investigation - Pomerantz LLP is investigating claims on behalf of Insulet investors regarding possible securities fraud or other unlawful business practices by the company and its officers [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Price Impact - On March 12, 2026, Insulet announced a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods due to a manufacturing issue identified through ongoing product monitoring [3]. - Following this announcement, Insulet's stock price fell by $16.23 per share, representing a 6.88% decrease, closing at $219.84 per share on March 13, 2026 [3].

Core Viewpoint - A class action lawsuit has been filed against Boston Scientific Corporation, alleging securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Boston Scientific and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until May 4, 2026, to request to be appointed as Lead Plaintiff if they purchased Boston Scientific securities during the Class Period [2]. Group 2: Financial Performance - On February 4, 2026, Boston Scientific reported lower-than-expected sales in its electrophysiology division and provided fiscal year 2026 guidance that fell short of analyst expectations [4]. - The company attributed its disappointing results and guidance to slower-than-expected market growth and increased competition [4]. - Following this news, Boston Scientific's stock price dropped by $16.12 per share, or 17.6%, closing at $75.50 per share on February 4, 2026 [4].

Core Viewpoint - A class action lawsuit has been filed against Trip.com Group Limited, alleging securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit is initiated by investors who purchased Trip.com securities during the Class Period and have until May 11, 2026, to apply as Lead Plaintiff [3]. - The complaint can be accessed through Pomerantz LLP's website [3]. Group 2: Regulatory Investigation - On January 14, 2026, it was reported that China is investigating Trip.com for alleged antitrust conduct, focusing on monopolistic practices [3]. - The State Administration for Market Regulation has accused Trip.com of abusing its market position and imposing unfair restrictions on merchants [3]. - Following the news of the investigation, Trip.com's American Depositary Receipt (ADR) price dropped by $12.90, or 17.05%, closing at $62.78 per ADR on the same day [3]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [4].

Group 1 - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Aquestive securities during the Class Period have until May 4, 2026, to request appointment as Lead Plaintiff [2] - The lawsuit follows a significant stock price drop of 37.04%, closing at $3.91 per share after the announcement of FDA deficiencies regarding Anaphylm [5][4] Group 2 - The FDA's letter indicated ongoing review of the Anaphylm New Drug Application, delaying approval indefinitely [4] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history in fighting for victims of securities fraud [6]

Core Viewpoint - A class action lawsuit has been filed against Grocery Outlet Holding Corp. concerning allegations of securities fraud and unlawful business practices [2]. Financial Performance - Grocery Outlet reported its fiscal year 2025 financial results, with adjusted EBITDA of $254.3 million, net sales of $4.69 billion, and diluted adjusted earnings per share of $0.76, all missing prior guidance [3]. - Comparable store sales increased by 0.5% on a 52-week basis, which was below the expected range of 0.6% to 0.9% [3]. Strategic Changes - The company announced an "optimization plan" in addition to its existing "restructuring plan," which includes the closure of 36 underperforming stores [3]. - Grocery Outlet recognized $110 million in non-cash charges related to the impairment of long-lived assets from the closure of these stores [3]. - Estimated restructuring charges for fiscal 2026 are projected to be between $14 million and $25 million, with significant cash expenditures for lease terminations and bad debt expenses [3]. Market Reaction - Following the announcement of the financial results and strategic changes, Grocery Outlet's stock price fell by $2.45 per share, or 27.87%, closing at $6.34 per share on March 5, 2026 [3].

Core Viewpoint - A class action lawsuit has been filed against monday.com Ltd. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether monday and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until May 11, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired monday securities during the Class Period [2]. Group 2: Financial Performance - On November 10, 2025, monday reported third-quarter financial results and issued softer guidance for the fourth quarter, leading to a stock price drop of $23.38 per share, or 12.33%, closing at $166.21 [4]. - On February 9, 2026, monday announced its fourth-quarter and fiscal year 2025 results, providing weaker guidance for 2026 and shifting away from its long-term revenue target of $1.8 billion for 2027, resulting in a stock price decline of $20.37 per share, or 20.79%, closing at $77.63 [5].

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging securities fraud and unlawful business practices related to the company's operations [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Corcept and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 21, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired Corcept securities during the Class Period [2]. Group 2: Stock Performance and Regulatory Issues - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant, stating that additional evidence of effectiveness was required [4]. - Following the FDA's announcement, Corcept's stock price dropped by $35.40 per share, or 50.4%, closing at $34.80 per share on the same day [4].

Core Viewpoint - A class action lawsuit has been filed against NuScale Power Corporation, alleging securities fraud and unlawful business practices related to significant financial losses and expenses incurred by the company [2][4]. Financial Performance - NuScale reported a dramatic increase in general and administrative expenses, which surged over 3,000% to $519 million in the third fiscal quarter, compared to $17 million in the same period the previous year [4]. - The company's quarterly net loss escalated to $532 million, up from $46 million in the prior year period [4]. Key Events - The spike in expenses was primarily attributed to a $495 million payment to ENTRA1 Energy LLC for an agreement to develop power plants for the Tennessee Valley Authority, which could involve milestone payments exceeding $3 billion [4]. - Following the financial disclosures, NuScale's stock price dropped by $7.57 per share, or 19.97%, closing at $30.34 per share on November 7, 2025 [5]. Legal Context - Investors who purchased NuScale securities during the class period have until April 20, 2026, to request appointment as Lead Plaintiff in the class action [2].

Core Viewpoint - Navan, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO offering documents, particularly regarding a significant increase in sales and marketing expenses shortly after the IPO [4][5]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled McCown v. Navan, Inc., was initiated against Navan and its executives for violations of the Securities Act of 1933 [1]. - Investors who purchased Navan's common stock during its IPO on October 31, 2025, have until April 24, 2026, to apply as lead plaintiffs in the lawsuit [1][7]. - The lawsuit claims that Navan's IPO documents were materially false or misleading, omitting critical information about a 39% increase in sales and marketing expenses [4]. Group 2: Financial Performance and Stock Impact - Navan's IPO involved the issuance of nearly 37 million shares at an offering price of $25.00 per share [3]. - Following the announcement of increased sales and marketing expenses to nearly $95 million (a 39% increase from $68.5 million), Navan's stock price fell nearly 12% [5]. - By the time the class action lawsuit commenced, Navan's stock had declined to as low as $9.20 per share, representing a nearly 63% drop from the IPO price [6]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is leading the class action lawsuit and is recognized as a top law firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [8].

Core Viewpoint - Eos Energy Enterprises, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with significant financial losses reported by investors during the specified class period [1][4]. Company Overview - Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems aimed at utility-scale commercial and industrial applications [3]. Allegations of the Lawsuit - The lawsuit claims that Eos Energy made false or misleading statements and failed to disclose critical operational issues, including: - Inability to achieve production and capacity utilization targets as per previous guidance [4]. - Battery line downtime exceeding industry norms and internal forecasts [4]. - Delays in automated bipolar production quality targets [4]. - Inadequate systems preventing accurate guidance and timely disclosures [4]. Financial Performance - On February 26, 2026, Eos Energy reported its fourth quarter and full year 2025 results, revealing: - Full year 2025 revenue of $114.2 million, significantly below the guidance of $150 million to $160 million [5]. - A gross loss of $143.8 million and a net loss attributable to shareholders of $969.6 million [5]. - An adjusted EBITDA loss of $219.1 million and a capacity milestone reached five weeks later than planned [5]. - Following this announcement, Eos Energy's stock price dropped by over 39% [5]. Legal Process - Investors who purchased Eos Energy securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6].